Esophageal carcinoma: Are modern targeted therapies shaking the rock?

Current Opinion in Oncology

Volumn 25, Issue 4, 2013, Pages 417-424

  Boland, Patrick M ^a   Burtness, Barbara ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

cancer; esophagogastric junction; esophagus; human epidermal growth factor receptor 2; targeted therapy

Indexed keywords

AFATINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MATUZUMAB; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM; RAMUCIRUMAB; SOMATOMEDIN C RECEPTOR; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN;

APICAL MEMBRANE; BREAST CANCER; CHEMORADIOTHERAPY; DISEASE CONTROL; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS FISTULA; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL HEMORRHAGE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LOWER ESOPHAGUS SPHINCTER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; STOMACH CARCINOMA; SURGICAL MORTALITY; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84879884170     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328362105e     Document Type: Review

References (86)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.
3. SEER: Survival Epidemiology and End Results Database. Bethesda, MD. http://seer.cancer.gov/statfacts/html/esoph.html. [Accessed 27 September 2012]
4. Wijnhoven BP, Tran KT, Esterman A, et al. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg 2007; 245:717-725. (Pubitemid 46684101)
5. Grotenhuis BA, van Heijl M, Zehetner J, et al. Surgical management of submucosal esophageal cancer: extended or regional lymphadenectomy? Ann Surg 2010; 252:823-830.
6. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20:1167-1174. (Pubitemid 34177421)
7. Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg 1996; 83:1174-1185. (Pubitemid 26290441)
8. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am 2009; 38:27-57.
9. Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005; 93:107-115. (Pubitemid 41076258)
10. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118:1173-1180. (Pubitemid 43185604)
11. Boone J, van Hillegersberg R, Offerhaus GJ, et al. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus 2009; 22:496-504.
12. Bandla S, Pennathur A, Luketich JD, et al. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg 2012; 93:1101-1106.
13. Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007; 109:658-667. (Pubitemid 46233226)
14. Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9:6461-6468. (Pubitemid 38031834)
15. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24:4922-4927. (Pubitemid 46630921)
16. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24:1612-1619. (Pubitemid 46638785)
17. Wang WP, Wang KN, Gao Q, Chen LQ. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction. World J Surg Oncol 2012; 10:14.
18. Adelstein DJ, Rodriguez CP, Rybicki LA, et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs 2012; 30:1684-1689.
19. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13:5869-5875. (Pubitemid 47583913)
20. Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011; 117:1409-1414.
21. Ferry DR, Dutton SJ, Mansoor W, et al. Phase III multicentre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib) ESMO. 2012;LBA20-PR.
22. Wainberg ZA, Lin LS, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011; 105:760-765.
23. Juergens RA, Gibson MK, Yang SC, et al. Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC) [abstract]. J Clin Oncol 2010; 28:. (suppl; abstr e14532).
24. Li G, Hu W, Wang J, et al. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 2010; 78:1407-1412.
25. Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 2011; 22:1367-1373.
26. Luber B, Deplazes J, Keller G, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2011; 11:509.
27. Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010; 28 (suppl 4006).
28. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21:2213-2219.
29. Waddell TS, Chau I, Barbachano Y, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) [abstract]. J Clin Oncol 2012; 30:. (suppl; LBA4000).
30. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697-4705.
31. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377:2103-2114.
32. Punt CJ. Drug development in advanced esophagogastric cancer: the art of extrapolation. J Clin Oncol 2010; 28:3907-3909.
33. Okines AF, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010; 28:3945-3950.
34. Tomblyn MB, Goldman BH, Thomas CR Jr, et al. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol 2012; 7:906-912.
35. De Vita F, Orditura M, Martinelli E, et al. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 2011; 104:427-432.
36. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, nonresectable, epithelial origin esophageal tumours with the humanized antiepidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012; 13:600-605.
37. Lledo G, Michel P, Dahan L, et al. Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX) [abstract]. J Clin Oncol 2011; 29 ((suppl 4; 8)).
38. Gibson MK, Catalano PJ, Kleinberg L, et al. E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus [abstract]. J Clin Oncol 28:15s, 2010 (suppl; 4064).
39. Yu JM, Wang JH, Sun X, et al. An open label, multicenter clinical study of cetuximab combined with concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Preliminary results of a phase II trial [abstract]. J Clin Oncol 2010; 28: (suppl; e14520).
40. Schubert L. Ethical implications of pharmacogenetics-do slippery slope arguments matter? Bioethics 2004; 18:361-378. (Pubitemid 38992318)
41. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
42. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182. (Pubitemid 17231334)
43. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5:63-69. (Pubitemid 38821193)
44. Ross JS, Mulcahy M. HER2 testing in gastric/gastroesophageal junction adenocarcinomas: unique features of a familiar test. Gastrointest Cancer Res 2011; 4:62-66.
45. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19:1523-1529.
46. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-697.
47. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16:273-278. (Pubitemid 40309309)
48. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23:2656-2662.
49. Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer 2012; 3:137-144.
50. Tafe LJ, Janjigian YY, Zaidinski M, et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011; 135:1460-1465.
51. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
52. Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses. 2008 Gastrointestinal Cancers Symposium.
53. Pishvaian M, Sakaeva D, Hsieh RK, et al. A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer [abstract]. J Clin Oncol 2011; 29 (suppl 4; 88).
54. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342. (Pubitemid 38702844)
55. Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist 2011; 16:844-858.
56. Kim SE, Shim KN, Jung SA, et al. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009; 3:88-94.
57. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24:5201-5206. (Pubitemid 46631363)
58. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29:3968-3976.
59. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30:2119-2127.
60. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor- 2. J Clin Oncol 2010; 28:780-787.
61. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011; 29:1449-1458.
62. Schmitt JM, Sommers SR, Fisher W, et al. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol 2012; 7:760-763.
63. Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28:2947-2951.
64. Ilson D, Goodman KA, Janjigian YY, et al. Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma [abstract]. J Clin Oncol 2012; 30(suppl 4; 67).
65. Bendell JC, Meluch A, Peyton J, et al. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol 2012; 10:430-437.
66. Astsaturov IA, Meyer JE, Cheng JD, et al. A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction [abstract]. J Clin Oncol 2012; 30(suppl 4; 74).
67. Hirashima K, Baba Y, Watanabe M, et al. Aberrant activation of the mTOR pathway and antitumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer 2012; 106:876-882.
68. Kim SH, Chau GC, Jang YH, et al. Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma. Hum Pathol 2012.
69. Van Cutsem E, Yeh KH, Bang YJ, et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1 [abstract]. J Clin Oncol 2012; 30(suppl 4; LBA3).
70. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011; 29:3126-3132.
71. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011; 3 (Suppl 1):S7-S19.
72. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043. (Pubitemid 46799492)
73. Tuynman JB, Lagarde SM, Ten Kate FJ, et al. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008; 98:1102-1108. (Pubitemid 351399800)
74. Hu YC, Lam KY, Law S, et al. Profiling of differentially expressed cancerrelated genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 2001; 7:3519-3525. (Pubitemid 33069989)
75. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29:4803-4810.
76. Oliner KS, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer [abstract]. J Clin Oncol 2012; 30(suppl; 4005).
77. McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs 2009; 18:1025-1033.
78. Higano CS, Yu EY, Whiting SH, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2007; (June 20 Supplement); 27(No 18S, 3505).
79. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
80. Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 2010; 16:1662-1672.
81. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmallcell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991. (Pubitemid 44343542)
82. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008; 44:54-60. (Pubitemid 350256935)
83. Kim MK, Cho KJ, Kwon GY, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008; 14:4225-4231.
84. Metzger R, Warnecke-Eberz U, Alakus H, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg 2012; 16:26-34.
85. Yoon HH, Catalano PJ, Murphy KM, et al. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer 2011; 11:176.
86. Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009; 20:1242-1248.